LUTATHERA
Peaklutetium lu 177 dotatate
Mechanism of Action
177 dotatate binds to somatostatin receptors with highest affinity for subtype 2 somatostatin receptors (SSTR2). Upon binding to somatostatin receptor expressing cells, including malignant somatostatin receptor-positive tumors, the compound is internalized. The beta-minus emission from lutetium-177…
Clinical Trials (5)
Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors
A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea
LUTATHERA Injection General Use Result Survey
Telotristat With Lutathera in Neuroendocrine Tumors
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)